Can I Take Resveratrol with Oral Micronized Progesterone (Prometrium)?

The Short Answer: What We Know and What We Do Not

There is no published randomized trial showing that resveratrol causes a clinically meaningful rise or fall in blood progesterone levels when taken alongside Prometrium. That absence of trial data is itself the problem. Most of what clinicians currently apply comes from in-vitro enzyme studies, pharmacokinetic modeling, and a small number of resveratrol trials in women with PCOS or breast-cancer risk, none of which measured serum progesterone as a primary outcome.

What we do know is that two distinct biological pathways create a plausible interaction signal.

Pathway 1: CYP3A4 Enzyme Competition

Oral micronized progesterone is absorbed from the gut and extensively metabolized by CYP3A4 in the intestinal wall and liver. Resveratrol, at concentrations achievable with supplement doses, has been shown in vitro to inhibit CYP3A4 activity. A 2006 enzyme-kinetics study found that trans-resveratrol inhibited CYP3A4 with an IC50 in the low-micromolar range, suggesting competitive inhibition of the enzyme. If CYP3A4 is partially inhibited, progesterone clearance slows and plasma progesterone levels may rise above the intended therapeutic window.

In practical terms, this is unlikely to be dramatic at typical supplement doses of 150 to 250 mg daily, but the effect could become more meaningful at the 500 mg to 1,000 mg doses some longevity-focused supplement stacks use.

Pathway 2: Estrogenic Receptor Activity

Resveratrol is a polyphenol that binds estrogen receptors alpha and beta, behaving as a selective estrogen receptor modulator (SERM)-like compound. Its net estrogenic or anti-estrogenic effect depends on which receptor subtype predominates in a given tissue. In breast tissue it shows predominantly anti-estrogenic signaling; in bone and the cardiovascular system it may show weak estrogenic agonist activity.

For a woman taking Prometrium as the progestogen component of combination hormone therapy alongside an estrogen, adding a compound with SERM-like properties means her effective estrogen receptor stimulation becomes harder for her clinician to predict or calibrate.

Why This Matters More for Women Than General Drug Interaction Guides Acknowledge

General drug interaction databases flag the CYP3A4 issue in passing. They rarely address how hormonal context changes the stakes. For women, three additional layers matter.

The Menstrual Cycle Changes Progesterone Pharmacokinetics

In women of reproductive age still cycling, endogenous progesterone rises naturally in the luteal phase (days 15 to 28 of a 28-day cycle), reaching serum peaks of 5 to 20 ng/mL. If a woman takes Prometrium for luteal-phase support in the context of fertility treatment or PCOS management, even a modest CYP3A4-mediated rise in exogenous progesterone exposure stacks on top of endogenous levels. Whether this produces clinical symptoms (sedation, breast tenderness, mood changes) depends on individual baseline, timing, and dose.

Perimenopause: The Stage Where Both Products Are Often Used Together

Women in perimenopause are the group most likely to be taking Prometrium for irregular cycles or early HRT, and also most likely to reach for resveratrol supplements marketed for cardiovascular health and longevity. Perimenopausal physiology already involves wide swings in estrogen and progesterone. Adding a SERM-like compound on top of exogenous progesterone could amplify symptom variability, making it harder to distinguish a dose-related side effect from the natural hormonal fluctuation of the transition itself.

Postmenopause: Endometrial Safety Is Non-Negotiable

In postmenopausal women on systemic estrogen therapy, Prometrium's primary job is endometrial protection. The PEPI trial established that unopposed estrogen sharply increases endometrial hyperplasia risk, and that micronized progesterone was among the progestogens that provided protection. Any factor that alters progesterone bioavailability, whether upward or downward, touches that protection. CYP3A4 inhibition raising progesterone exposure is probably not the direction of concern here, but it does underscore that progesterone levels are not something to treat casually.

What the Resveratrol-in-Women Evidence Actually Shows

Resveratrol has been studied directly in women in a handful of trials, and the findings are relevant even though none measured Prometrium co-administration.

A 2016 randomized controlled trial in 80 postmenopausal women found that 75 mg of resveratrol twice daily for 14 weeks improved cognitive performance and cerebrovascular function compared with placebo, with no serious adverse events. Hormone levels were not the primary endpoint, limiting what can be concluded about steroid metabolism.

A 2015 trial published in Fertility and Sterility enrolled 30 women with PCOS and found that 1,500 mg of resveratrol daily for three months reduced total testosterone by 23.1% and lowered DHEAS, suggesting resveratrol does influence the steroidogenic pathway, at least in PCOS. This is a steroid-hormone effect, not a direct progesterone measurement, but it confirms the compound does not sit inertly outside the endocrine system.

A useful clinical framework: think of resveratrol's interaction with Prometrium as sitting on a spectrum from "probably negligible at low doses with brief use" to "worth monitoring if doses are high, use is chronic, or the woman has hormone-sensitive conditions." The spectrum looks like this:

| Scenario | Interaction Risk Level | Suggested Action | |---|---|---| | Resveratrol <250 mg/day, short-term (<4 weeks) | Low | Disclose to clinician; no dose change needed in most cases | | Resveratrol 250-500 mg/day, ongoing HRT | Moderate | Clinician review; consider symptom diary | | Resveratrol >500 mg/day, any Prometrium dose | Moderate-High | Do not self-initiate; clinician must assess | | PCOS + Prometrium + resveratrol, reproductive years | Moderate (hormonal complexity) | Endocrine or gynecology review before starting | | Hormone-sensitive cancer history + Prometrium + resveratrol | Requires oncologist input | Do not combine without specialist clearance |

Pregnancy and Lactation: Read This Before Taking Either

Prometrium in pregnancy: Oral micronized progesterone carries FDA Pregnancy Category B labeling, meaning animal reproduction studies showed no fetal harm but adequate and well-controlled studies in pregnant women are lacking. Progesterone supplementation is commonly used in the first trimester to support luteal function in women with a history of recurrent pregnancy loss or undergoing assisted reproduction. The PROMISE trial found that vaginal micronized progesterone did not significantly increase live birth rates in women with unexplained recurrent miscarriage, though the PRISM trial found benefit in women with a history of miscarriage who had first-trimester bleeding. If you are pregnant and already taking Prometrium, do not stop it without consulting your OB or reproductive endocrinologist.

Resveratrol in pregnancy: do not take it. Resveratrol is present in red wine, but supplement-level doses (150 mg to 1,500 mg daily) have not been established as safe in human pregnancy. Animal data show that high-dose resveratrol can alter fetal growth and pancreatic development. No adequate human pregnancy safety data exist. Stop resveratrol supplements before attempting conception and throughout pregnancy and breastfeeding.

Lactation: Prometrium transfers into breast milk in small amounts. The drug label notes that progesterone is detectable in human milk and caution is recommended. Resveratrol transfer into breast milk has not been adequately studied; the precautionary position is to avoid it during lactation.

Contraception note: Prometrium is not a contraceptive. Women of reproductive age using it for cycle regulation or HRT support who do not wish to become pregnant need reliable contraception separately. Resveratrol does not provide contraceptive protection.

Who This Combination May Be Right For, and Who Should Be More Careful

Women Who Can Likely Use Both With Clinician Oversight

Postmenopausal women on stable HRT with Prometrium who wish to add low-dose resveratrol (<250 mg daily) for cardiovascular or cognitive reasons are the group with the lowest interaction risk. The estrogenic ambiguity of resveratrol is less acutely relevant in the absence of cycling, and the CYP3A4 effect at low doses is unlikely to cause a meaningful rise in progesterone beyond the intended range.

Women Who Need More Caution

Women with PCOS who are taking Prometrium to regulate cycles face a more complex hormonal picture. Resveratrol's effect on androgens and the steroidogenic pathway in PCOS is real, as the 2015 Fertility and Sterility trial showed, and adding it without specialist input could make it harder to attribute symptom changes to the right cause.

Women in active perimenopause with unpredictable cycles, high symptom burden (night sweats, mood instability), and new or recently adjusted Prometrium doses should stabilize on their HRT regimen before adding any supplement with hormonal activity.

Women with a personal or family history of hormone-sensitive cancers (estrogen receptor-positive breast cancer, endometrial cancer) should not self-initiate resveratrol alongside any progestogen without discussing it with their oncologist. The SERM-like activity of resveratrol in breast tissue is generally considered anti-estrogenic in lab studies, but translating that to clinical safety for a specific individual with a cancer history requires specialist judgment.

Practical Monitoring: What to Watch For

If you and your clinician decide it is appropriate to continue both, a few monitoring steps make the combination safer.

Symptom diary. Track progesterone-excess symptoms: breast tenderness, bloating, mood changes, increased fatigue, and sedation (Prometrium is taken at night partly because it causes drowsiness). A CYP3A4-mediated rise in progesterone levels would show up as more pronounced versions of these symptoms.

Serum progesterone, if clinically indicated. There is no standard guideline mandating routine progesterone levels in all HRT users, but if you develop unexpected side effects after adding resveratrol, a fasted serum progesterone drawn at a consistent point in your cycle or regimen gives your clinician actionable information.

Timing separation. While no published data confirm that taking the two products hours apart reduces interaction magnitude, spacing them (for example, resveratrol with breakfast, Prometrium at bedtime as labeled) minimizes the period during which both are being absorbed simultaneously and competing at the intestinal CYP3A4 level. This is precautionary, not evidence-based.

Annual endometrial assessment if symptoms change. Postmenopausal women on HRT who develop any unexpected spotting or bleeding need prompt evaluation regardless of supplement use.

Resveratrol's Other Drug Interactions: Context for Women on Multiple Medications

Women managing perimenopause or menopause often take several agents simultaneously: statins, antihypertensives, thyroid medications, SSRIs. Resveratrol inhibits not only CYP3A4 but also CYP2C9 and may inhibit P-glycoprotein at higher doses, according to in-vitro data reviewed by the NIH Office of Dietary Supplements. This matters because:

• Warfarin is metabolized by CYP2C9. Women on warfarin should not add resveratrol without INR monitoring.
• Some statins (simvastatin, lovastatin) are CYP3A4 substrates. Elevated statin exposure raises myopathy risk.
• Levothyroxine absorption may be affected by polyphenol supplements taken simultaneously, though the specific interaction with resveratrol has not been directly quantified.

The point is not to list every possible interaction but to flag that resveratrol's enzyme inhibition profile means it does not interact in isolation. In the context of a full medication and supplement review, the Prometrium interaction is one piece of a larger picture your clinician needs to see.

The Evidence Gap: What We Still Do Not Know

Women have been systematically underrepresented in pharmacokinetic studies. Progesterone's CYP3A4-dependent metabolism has been characterized mostly in mixed-sex populations or in vitro systems, not in prospective trials of postmenopausal women on combination HRT. The same is true of resveratrol's enzyme-inhibition data: the IC50 values come from liver microsome preparations, not from pharmacokinetic studies in women taking standard supplement doses.

No published trial has enrolled women on Prometrium, given them resveratrol at a defined dose, and measured progesterone AUC or serum trough levels before and after. That trial does not exist. What this means for you: the absence of a confirmed clinically significant interaction is not the same as confirmed safety. The interaction is biologically plausible, mechanistically supported, and not yet quantified in real women.

The Menopause Society (formerly NAMS) states that most botanical and supplement interactions with hormone therapy are inadequately studied and that women should disclose all supplement use to their clinician. That guidance applies directly here.

What to Tell Your Clinician

Bring a complete supplement list to your next appointment. Specifically note:

• The brand and dose of resveratrol (trans-resveratrol vs. A blend; dose in milligrams per capsule)
• How long you have been taking it
• Whether you are taking any other supplements that also inhibit CYP3A4 (grapefruit products, St. John's wort in reverse direction, black cohosh)
• Any new symptoms that began after adding resveratrol

Your clinician can then decide whether a serum progesterone level is warranted, whether the dose of Prometrium should be reviewed, or whether the resveratrol adds enough benefit to justify the monitoring burden.

At 100 mg nightly (the standard endometrial-protection dose) there is likely a wider safety margin than at 200 mg nightly, which is the dose used for secondary amenorrhea. A woman on the higher dose has less pharmacokinetic buffer if CYP3A4 activity shifts.